ID   NK-92MIhCD64
DR   Wikidata; Q54930661
RX   PubMed=28415754;
CC   Characteristics: Transfected with the CD64-BB-zeta construct that consist of a signal peptide, the FCGR1A/CD64 extracellular domain, the CD8A extracellular domain, the CD28 TM and co-activation domains, the 4-1BB co-activation domain and finally the CD3Z signaling domain.
CC   Transfected with: HGNC; 3613; FCGR1A (extracellular domain).
CC   Transfected with: HGNC; 6001; IL2.
CC   Caution: NantKwest exclusively owns, controls and distributes NK-92MI. This CD64-modified variant of NK-92MI was created by a research group and is governed by a Material Transfer Agreement that prevents them from legally distributing the cells to any third party.
CC   Derived from sampling site: Peripheral blood.
DI   NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_3755 ! NK-92MI
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 22-08-17; Last updated: 07-09-18; Version: 3
RX   PubMed=28415754; DOI=10.18632/oncotarget.16201;
RA   Chen Y., You F.-T., Jiang L.-C., Li J.-L., Zhu X.J., Bao Y.-Y., Sun X.,
RA   Tang X.-W., Meng H.-M., An G.-L., Zhang B.-Z., Yang L.;
RT   "Gene-modified NK-92MI cells expressing a chimeric CD16-BB-zeta or
RT   CD64-BB-zeta receptor exhibit enhanced cancer-killing ability in
RT   combination with therapeutic antibody.";
RL   Oncotarget 8:37128-37139(2017).